Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7615716 | 0.85 | MEN1 (0.56) | MEN1KMT2AKDM4EL3MBTL1NPC1 | |
| SCHEMBL7095263 | 0.82 | MEN1 (0.66) | MEN1KMT2AKDM4EL3MBTL1NPC1 | |
| SCHEMBL22609140 | 0.81 | MDM2 (0.52) | MEN1KMT2AKDM4EL3MBTL1RAB9A | |
| SCHEMBL3860393 | 0.81 | ICMT (0.58) | MEN1KMT2AALDH1A1NPSR1EPHX1 | |
| SCHEMBL8702672 | 0.81 | MEN1 (0.64) | MEN1KMT2AKDM4EL3MBTL1NPC1 | |
| SCHEMBL7613993 | 0.80 | MTOR (0.53) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL19305856 | 0.80 | LMNA (0.54) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL7611007 | 0.80 | ICMT (0.61) | MEN1KMT2AALDH1A1NPSR1EPHX1 | |
| SCHEMBL7621060 | 0.80 | ICMT (0.61) | MEN1KMT2AALDH1A1NPSR1EPHX1 | |
| SCHEMBL11617578 | 0.79 | MEN1 (0.62) | MEN1KMT2AKDM4EL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777471-B1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING & MFG (US) | 2002-11-27 | — | — | EP | claimed |
| EP-0777471-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-11 | — | — | EP | claimed |
| WO-1996003983-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-15 | — | — | WO | claimed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1750704-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113537-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-0777471-B1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING & MFG (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-0777471-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5612377-A | OXYUREA DERIVATIVE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996003983-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | MEN1 2562/4885KMT2A 3336/4885KDM4E 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.